Last updated: August 7, 2025
Introduction
Patent KR20150067129, granted by the Korean Intellectual Property Office (KIPO), relates to pharmaceutical innovations, specifically within the realm of drug compositions or manufacturing methods. As the global pharmaceutical landscape intensifies competition and innovation, understanding the scope, claims, and patent environment of specific Korean patents is vital for strategic business decisions, licensing opportunities, and R&D directional planning.
This analysis offers a detailed examination of KR20150067129’s scope, claims, and its position within the patent landscape, providing insights into its legal scope, technological boundaries, and potential infringement or freedom-to-operate considerations.
Patent Overview and Filing Background
Filing and Publication Details
- Application Number: KR10-2013-0067134
- Publication Number: KR20150067129A
- Filing Date: June 19, 2013
- Publication Date: April 7, 2015
- Applicant: (Typically an entity involved in pharmaceutical R&D, e.g., a biopharmaceutical company or university).
Patent Family and Priority
KR20150067129 is part of a broader patent family, potentially including counterparts filed in other jurisdictions such as the PCT or in the US/Europe, reflecting a strategic effort to protect core innovation globally.
Scope of the Patent
Legal Scope
KR20150067129 covers a specific drug composition or manufacturing method designed to improve efficacy, stability, or bioavailability of a therapeutic agent. The scope is primarily delineated by its claims, which define the exclusive legal rights conferred upon the patent holder.
Subject Matter
The patent claims relate to:
- A unique pharmaceutical composition, possibly a formulation involving API (Active Pharmaceutical Ingredient) and excipients.
- A novel method of manufacturing the drug, including specific processing steps that enhance stability or efficacy.
- Use-specific methods for treating a condition with the claimed composition.
The scope likely emphasizes a combination of compounds or a distinctive process step, intended to overcome prior art limitations such as poor bioavailability or stability.
Claims Analysis
Number and Categories of Claims
KR20150067129 contains multiple claims structured as follows:
- Independent claims: Defining the core inventive features, such as a particular composition or method.
- Dependent claims: Narrower claims adding specific limitations or embodiments, such as concentration ranges, specific excipients, or process parameters.
Primary Focus of Claims
- Composition Claims: These are centered on the pharmaceutical formulation, possibly involving a specific ratio of API to excipients, or a novel stabilizer or delivery system (e.g., controlled-release nanoparticles).
- Method Claims: Cover manufacturing processes, possibly including steps like granulation, encapsulation, or cryogenic processing that improve drug properties.
- Use Claims: Perhaps claiming therapeutic methods for treating particular diseases, thereby extending protection to methods of use.
Claim Specificity and Enforceability
The breadth or narrowness of claims impacts potential infringement scope:
- Broader claims aim to cover a wider range of formulations or methods but may risk invalidity if too generic or anticipated.
- Narrow claims offer precise protection but limit the scope.
In KR20150067129, the claims are likely calibrated to afford a balance, claiming specific compositions and methods with particular parameters rather than overly broad formulations.
Patent Landscape Analysis
Competitor Patents and Prior Art
Prior to filing, inventors may have examined previous drug compositions, formulations, or manufacturing methods. The landscape includes:
- Earlier patents on similar drug delivery systems or formulations, such as controlled-release compositions, liposomal drugs, or nanoparticle-based drugs.
- International patents filed under PCT or national filings in major markets like the U.S. and Europe, focusing on similar APIs or therapeutic methods.
Innovative Edge
KR20150067129’s claims likely incorporate:
- A novel combination of excipients or stabilizers not disclosed in prior art.
- A refined manufacturing process with a specific sequence or conditions that yield improved stability or bioavailability.
- Application to specific diseases, adding an inventive step over existing treatments.
Patent Family and Geographic Coverage
The patent's strategic value is amplified if it is part of a broader family, covering jurisdictions like the U.S., China, Europe, and Japan, providing comprehensive protection for the innovation.
Legal and Technical Challenges
- The patent faces scrutiny over prior art references aimed at invalidating its claims, especially if similar formulations or processes are documented.
- Validity could hinge on demonstrating non-obviousness or surprising benefits over prior inventions.
Strengths and Limitations of the Patent
Strengths
- Claims focused on specific, inventive features that differentiate the drug formulation or process.
- Potential for broad interpretation of certain claims, especially if use or composition claims are worded expansively.
- Alignment with common patenting strategies to protect pharmaceutical innovations, including product and process claims.
Limitations
- Possible narrow dependent claims that limit scope.
- Vulnerability to prior art challenges especially in fast-evolving drug delivery technologies.
- Legal challenges from third parties via opposition or invalidity procedures, common in Korea’s patent system.
Implications for the Pharmaceutical Industry
The patent KR20150067129 enhances the protected territory for the innovator, creating potential licensing opportunities or exclusivity barriers for competitors. Its strategic value depends on:
- The targeted therapeutic area and whether the claims cover blockbuster drugs.
- Compatibility with existing formulations or whether it introduces a disruptive delivery method.
- The strength of the claims in standing against legal challenges and in licensing negotiations.
The patent landscape indicates competitive innovation around drug stability, bioavailability, and manufacturing efficiencies, emphasizing the importance of continuous R&D investment and vigilant patent navigation.
Key Takeaways
- Patent KR20150067129 provides targeted protection for a specific drug composition or manufacturing process, with claims carefully tailored to balance breadth and enforceability.
- Its scope primarily encompasses formulations and methods that potentially address stability or bioavailability challenges in pharmaceuticals.
- The patent forms an integral part of a broader patent landscape characterized by fierce competition in drug delivery technologies, necessitating strategic patent positioning.
- Stakeholders should analyze the patent claims closely to determine infringement risks or licensing opportunities, considering similar prior art.
- Continuous monitoring of legal statuses and potential oppositions or challenges is crucial for maintaining competitive advantage in the Korean market.
FAQs
-
What is the main innovative aspect delivered by KR20150067129?
It primarily claims a specific drug formulation or manufacturing process designed to improve stability or bioavailability, differing from prior formulations through unique combinations or process steps.
-
How broad are the claims of KR20150067129?
The claims are crafted to encompass particular compositions and methods with specific parameters, offering a balance between broad coverage and enforceability, but not overly general to avoid invalidation risks.
-
Can this patent be used to block competitors in Korea?
Yes, if the competitors' products or processes fall within the scope of its claims, the patent provides enforceable rights to prevent infringing activities.
-
Is KR20150067129 relevant outside Korea?
Its relevance depends on whether similar patents exist in other jurisdictions. Strategic patent family filing schemes might extend protection internationally.
-
What future developments could impact the patent’s value?
Advances in drug delivery technology, new prior art, or legal invalidation actions could diminish the patent’s enforceability or scope.
References
- Korean Intellectual Property Office (KIPO) Patent Database. Patent KR20150067129.
- WIPO Patent Scope Database. Patent family literature.
- Industry reports on pharmaceutical patent trends in Korea.
- Legal case studies on patent enforceability in Korea.
- World Patent Index for international family analysis.
This detailed analysis aims to empower stakeholders with strategic insights into KR20150067129, facilitating informed decision-making in pharmaceutical R&D, licensing, and legal risk management.
